Cargando…

Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?

Detalles Bibliográficos
Autores principales:	Ma, Zhongren, Li, Pengfei, Ikram, Aqsa, Pan, Qiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414423/ https://www.ncbi.nlm.nih.gov/pubmed/32863136 http://dx.doi.org/10.1016/j.it.2020.08.002

Ejemplares similares

Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses
por: Ma, Zhongren, et al.
Publicado: (2020)

Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context
por: Li, Pengfei, et al.
Publicado: (2020)

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
por: Anderson, Danielle E., et al.
Publicado: (2020)

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
por: Zheng, Qinyue, et al.
Publicado: (2023)

Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses
por: Zeng, Lei-Ping, et al.
Publicado: (2017)

Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
por: Jiang, Shibo, et al.
Publicado: (2020)

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
por: Chen, Yanjia, et al.
Publicado: (2022)

The presence of anti–SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes
por: Liu, Yang, et al.
Publicado: (2022)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

HEV prevalence and potential risk factors in a large multi-ethnic youth cohort in China
por: Li, Huixia, et al.
Publicado: (2021)

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
por: Wang, Pengfei, et al.
Publicado: (2020)

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
por: Tober-Lau, Pinkus, et al.
Publicado: (2022)

The Impact of Mutations on the Pathogenic and Antigenic Activity of SARS-CoV-2 during the First Wave of the COVID-19 Pandemic: A Comprehensive Immunoinformatics Analysis
por: Baloch, Zulqarnain, et al.
Publicado: (2021)

Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations
por: Li, Pengfei, et al.
Publicado: (2022)

Repurposing dyphylline as a pan-coronavirus antiviral therapy
por: Wang, Yining, et al.
Publicado: (2022)

Authors’ response: Plenty of coronaviruses but no SARS-CoV-2
por: Reusken, Chantal B, et al.
Publicado: (2020)

Letter to the editor: Plenty of coronaviruses but no SARS-CoV-2
por: Colson, Philippe, et al.
Publicado: (2020)

RBD(206)-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern
por: Zhou, Chuge, et al.
Publicado: (2021)

Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
por: Sharun, Khan, et al.
Publicado: (2021)

SARS-CoV-2 re-infection, vaccination and neutralizing antibodies
por: Bongiovanni, Marco, et al.
Publicado: (2022)

Breathing Is Enough: For the Spread of Influenza Virus and SARS-CoV-2 by Breathing Only
por: Scheuch, Gerhard
Publicado: (2020)

Superior mesenteric vein thrombosis as the only manifestation of SARS-CoV-2 infection()
por: Navarro-Martínez, Sergio, et al.
Publicado: (2022)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

Reply to Fillmore et al.: Additional evidence of non–SARS-CoV-2 coronavirus cross-immunity
por: Solomon, Matthew D., et al.
Publicado: (2022)

Neutralization of ARCoV-induced sera against SARS-CoV-2 variants
por: Li, Xiao-Feng, et al.
Publicado: (2022)

Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions
por: Wang, Yining, et al.
Publicado: (2022)

Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19
por: Liu, Pengcheng, et al.
Publicado: (2020)

Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine
por: Zhou, Xingdong, et al.
Publicado: (2021)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

Possible drawbacks of relying only on molecular testing for diagnosing SARS-CoV-2 infections
por: Lippi, G., et al.
Publicado: (2022)

Down‐regulation of SARS‐CoV‐2 neutralizing antibodies in vaccinated smokers
por: Zhang, Jiahui, et al.
Publicado: (2022)

Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
por: Yue, Lei, et al.
Publicado: (2021)

Early seasonal coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies
por: Wong, Lydia Su Yin, et al.
Publicado: (2023)

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

Canine Coronavirus: Not Only an Enteric Pathogen
por: Decaro, Nicola, et al.
Publicado: (2011)

Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

How Does SARS-CoV-2 Fragment the QRS?
por: Finsterer, Josef
Publicado: (2022)

Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
por: Wang, Lidong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ahemgsfennbs5om61bksch8hu